Less anti-infliximab antibody formation in paediatric Crohn patients on concomitant immunomodulators
Journal of Pediatric Gastroenterology and Nutrition Sep 28, 2017
Kansen HM, et al. - This encompassed the assessment of the consequence of immunomodulators on the formation of antibodies to infliximab (ATI) in paediatric patients with Crohn's disease (CD) and the association of ATI and loss of response. A link was brought to light between combination therapy with a notable reduction of antibody formation and prolonged effectivity in children with CD, compared to infliximab (IFX) monotherapy. It was reported that early combined immunosuppression (ECI) for at least 12 months, followed by IFX monotherapy, could be an equally effective alternative to continuous combined immunosuppression (CCI).
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries